S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
James F. Oliviero III, the CEO, President, and Director of Checkpoint Therapeutics , Inc. (NASDAQ:CKPT), recently sold shares worth $64,027 in two separate transactions. The company, currently valued at $153 million, has seen its stock decline 16% over the past week, according to InvestingPro data. The sales, executed on February 7 and February 10, involved a total of 19,564 shares, sold at prices ranging from $3.15 to $3.41 per share. These transactions were conducted to satisfy tax withholding obligations related to the vesting of restricted shares. Following these sales, Oliviero holds 3,775,019 shares of the company. InvestingPro analysis reveals the company faces liquidity challenges with short-term obligations exceeding liquid assets, while analyst price targets range from $7 to $20, suggesting potential upside. Get access to 8 additional ProTips and comprehensive financial metrics with InvestingPro.
In other recent news, Checkpoint Therapeutics has been garnering attention from various analyst firms. Boral (OTC:BOALY) Capital initiated coverage of the biopharmaceutical company, giving it a Buy rating. The firm’s confidence in Checkpoint Therapeutics is largely due to the recent approval of its lead drug, UNLOXCYT. Boral Capital believes UNLOXCYT’s unique design and favorable adverse event profile give it a competitive edge in the immuno-oncology market.
In addition to Boral Capital’s positive outlook, Lake Street Capital Markets raised its price target for Checkpoint Therapeutics from $4.00 to $7.00, maintaining a Buy rating. The firm expects continued growth for the company into 2025, citing strong financial position and persistent demand trends.
In other recent developments, Checkpoint Therapeutics announced the continuation of Garrett Gray as Chief Financial Officer through a new executive employment agreement effective January 7, 2025. The agreement outlines Gray’s compensation and terms for severance in various termination scenarios, demonstrating the company’s commitment to its leadership’s stability. These recent developments could be of interest to investors tracking Checkpoint Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.